One of the underlying mechanisms of multidrug resistance (MDR) is over expression of mdr1 gene and its production of P-glycoprotein (Pgp) which acts as a drug efflux pump. Therefore, a key step for reversal of MDR is to inhibit the Pgp synthesis and function. One of the strategies to overcome multidrug resistance is the combination of anticancer agents with a modulator. Verapamil, for example, is an effective modulator and is able to bind to Pgp and block the Pgp function. Nevertheless, high-dose verapamil is required for effective reversal of MDR phenotype, dose-related cardiovascular toxicities limit its clinical application unfortunately.
Figure 1
Analysis of anti-mdr1 ribozyme expression by dot blots. Total cellular RNA (20 g) was hybridized with the ribozyme core sequence. Lane 1, K562R; lane 2, K562R transfected with empty vector; lanes 3-8, K562R transfected with anti-mdr1 ribozyme vector in six monoclonies. 
Figure 2
Analysis of mdr1 mRNA expression by RT-PCR. Total cellular RNA (10 g) was reverse transcribed and amplified by PCR with primers specific for mdr1 and ␤-actin as an internal control. Lane 1, K562R; lane 3, K562R transfected with empty vector; lanes 3-8, K562R transfected with anti-mdr1 ribozyme vector in six monoclonies; lane 9, sensitive K562 cell. M, DNA markers, from top to bottom, 2000 bp, 1000 bp, 750 bp, 500 bp, 250 bp, 100 bp.
( Figure 2 ). The primer sequences used for mdr1 amplification were as follows: 5Ј-CCC ATC ATT GCA ATA GCA GG-3Ј and 5Ј-GTT CAA ACT TCT GCT CCT GA-3Ј. ␤-actin was used as a control. The primer sequences for the ␤-actin were: 5ЈCCC TGG ACT TCG AGC AAG AGA AT-3Ј and 5Ј-GTT TTC TGC GCA AGT TAG G-3Ј. The 157-bp band of mdr1 transcripts decreased in ribozyme-transfected k562R cells (lanes 3-8). In contrast, untransfected or empty vector-transected cells showed a strong 157-bp band (lanes 1, 2). The sensitive K562 cell line did not show a 157-bp band (lane 9). The data suggest that the mdr1-ribozyme specifically inhibits expression of the mdr1 transcripts in ribozyme-transfected K562R cells.
The amount of Pgp on the cell surface was quantitatively analyzed by flow cytometry as described. 5 The results are shown in Table 1 . The fluorescence intensity of Pgp expression in the transfected K562R cells with anti-mdr-1 ribozyme was lower than that of untransfected parent cells. This indicated that the expression of Pgp in ribozyme transfected K562R cells had decreased. The empty vector did not alter Pgp expresssion. Levels of Pgp expression by flow cytometric analyses were consistant with those of RT-PCR.
Cell drug sensitivity to daunorubicin was determined using an MTT assay. The results are shown in Table 2 . In ribozyme-transfected cells, the resistance obviously decreased, but was not restored to the same degree as sensitive cell lines. In untransfected K562R cells, verapamil produced an apparently dose-dependent increase in sensitivity of K562R to DNR, the maximal reversal (verapamil 10 M) was 20-fold. In contrast, the sensitivity of K562R with anti-mdr ribozyme cells was able to be restored completely by combining verapamil even if verapamil was at a lower concentration (1 M). Transfecting with empty vector has no effect on the sensitivity to an anticancer drug. These results suggested that the combination of anti-mdr1 ribozyme and verapamil have synergistic effects on reversing multidrug resistance. This indicates that in combination with ribozyme, an efficient dose of verapamil to reverse MDR can be reduced to the degree that serious toxicity limiting its clinical application will not appear in clinical MDR reversal. This will be one possible strategy to reverse MDR and may be used as a new therapy in the treatment of patients with anticancerresistant leukemia and other cancers.
